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The aim of this study was to establish an immunohistochemical protein profile to complement preoperative staging and identify rectal
cancer patients at high-risk of adverse outcome. Immunohistochemistry was performed on a tissue microarray including 482 rectal
cancers for APAF-1, EphB2, MST1, Ki67, p53, RHAMM, RKIP and CD8
þ tumour infiltrating lymphocytes (TILs). After resampling of
the data and multivariable analysis, the most reproducible markers were combined and prognosis evaluated as stratified by pT and
pN status. In multivariable analysis, only positive RHAMM (Po0.001; HR¼1.94 (1.44–2.61)) and loss of CD8
þ TILs (P¼0.006;
HR¼0.63 (0.45–0.88)) were independent prognostic factors. The 5-year cancer-specific survival rate for RHAMMþ/TIL  patients
was 30% (95% CI 21–40%) compared to 76% (95% CI: 66–84%) for RHAMM /TILþ patients (Po0.001). The 5-year cancer-
specific survival of T1/T2/RHAMMþ/TIL  patients was 48% (20–72%) and significantly worse compared to T3/T4/RHAMM /
TILþ patients (71% 95% CI 56–82%); P¼0.039). Stratifying by nodal status, only Nþ/RHAMMþ/TIL  patients demonstrated
a significantly worse prognosis than N0/RHAMMþ/TIL  patients (P¼0.005). Loss of CD8
þ TILs was predictive of local recurrence
in RHAMMþ tumours (P¼0.009) only. RHAMM and CD8
þ TILs may assist in identifying early stage rectal cancer patients facing
a particularly poor prognosis and who may derive a benefit from preoperative therapy.
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Preoperative radio- and chemoradiotherapy are now considered an
integral part of treatment for patients with rectal cancer and can
result in considerable tumour downstaging, downsizing or even
complete pathological response in 20–30% of cases (Bosset et al,
2006; Mohiuddin et al, 2006). Even with total mesorectal excision
(TME), neoadjuvant therapy continues to improve clinical out-
come in patients with rectal cancer (den Dulk et al, 2008). The
selection of patients for preoperative therapy is largely based on
clinical staging made by endorectal ultrasound (EUS), computed
tomography (CT) or magnetic resonance imaging (MRI). Biologi-
cal markers predictive of poor clinical outcome from the
preoperative biopsy would be useful tools to complement clinical
staging. To date, such biological markers have had limited impact,
including both the molecular analysis of K-ras and p53, as well as
immunohistochemical markers (Turner et al, 2007; Guillem et al,
2008). There is currently no tissue-based marker, which is
recommended as a prognostic factor by the European Group on
Tumour Markers for patients with rectal cancer (Duffy et al, 2007).
Possible reasons may include the difficulty in interpreting results
from small studies, statistical analysis restricted to a single marker
and the use of scoring methods for assessing immunoreactivity,
which often may lack validation.
The aim of this study was to establish, using eight protein
markers, an immunohistochemical protein profile, which can be
applied in the preoperative setting to complement staging and help
to identify patients with a high-risk of adverse outcome. The
markers were selected for their representations of different cellular
processes and for their established or potential prognostic value.
In particular, apoptosis protease activating factor -1 (APAF-1) and
mammalian sterile20-like kinase 1 are proapoptotic proteins, the
reduced expression of these relate to adverse survival (Teraishi
et al, 2006; Paik et al, 2007; Ren et al, 2008). Loss of Ephrin B2
receptor (EphB2) and the metastasis suppressor Raf-1 kinase
inhibitor protein (RKIP) have been linked with poor outcome
(Jubb et al, 2005; Al-Mulla et al, 2006), whereas expression of Ki67
and p53 have led to conflicting reports (Kyzer and Gordon, 1997;
Munro et al, 2005). The receptor for hyaluronic acid-mediated
motility (RHAMM) mediates both Ras and TGF-b signalling
pathways and is associated with poor prognosis in a variety of
tumour entities (Wang et al, 1998; Maxwell et al, 2004; Hamilton
et al, 2007). Finally, CD8
þ tumour infiltrating lymphocytes (TILs)
have been linked to improved survival in colorectal cancer patients
(Chiba et al, 2004; Galon et al, 2006). This study was carried out on
482 preoperatively untreated rectal tumours, using a reproducible
scoring method, a systematic approach to determining negative or
positive protein marker expression and validation of prognostic
effects by resampling of the data.
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Patients
The patient collective was derived from three centres and included
1420 non-consecutive patients with primary colorectal cancer
treated from 1987 to 1996 at the Institute of Pathology, University
Hospital of Basel, Switzerland, the Institute of Clinical Pathology,
Basel Switzerland and the Institute of Pathology, Stadtspital
Triemli, Zu ¨rich, Switzerland.
Tissue microarray (TMA) and immunohistochemistry
These 1420 colorectal cancers were retrospectively collected.
Pathology was systematically reassessed for all cases. A TMA
consisting of these tissues was constructed as described previously
(Sauter et al, 2003). Clinicopathological data were available for all
patients included on the TMA. The use of tissue for this study was
approved by the local Ethics committee of the University Hospital
of Basel.
Briefly, the 1420 colorectal cancers were dewaxed and rehy-
drated in dH2O. Antigen retrieval was performed using a pressure
cooker in 0.001M ethylenediaminetetraacetic acid (EDTA) pH 8.0.
Endogenous peroxidase activity was blocked using 0.5% H2O2, and
the sections were incubated with 10% normal goat serum (Dako
Cytomation, Carpinteria, CA, USA) for 20min. Tissues were
incubated with primary antibodies for APAF-1 (clone NCL APAF-
1, Novocastra, Newcastle UK, 1:40), EphB2 (clone AF467, R&D
Systems, Minneapolis, MN, USA, 1:200), Ki67 (clone MIB-1, Dako
Cytomation, Glostrup, Denmark, 1:100), MST1 (polyclonal, Cell
Signaling, Danvers, MA, USA, 1:200), p53 (clone DO-7, Dako
Cytomation, Carpinteria, CA, USA, 1:200), RHAMM (clone 2D6,
Novocastra, Newcastle, UK, 1:100), RKIP (polylonal, Upsatet, New
York, NY, USA, 1:1000) and finally CD8
þ TILs (clone C8\144B,
1:100). Subsequently, sections were incubated with HRP-con-
jugated secondary antibody (DakoCytomation) for 30min at room
temperature. For visualisation of the antigen, the sections were
immersed in 3-amino-9-ethylcarbazoleþsubstrate-chromogen
(DakoCytomation) for 30min, and counterstained with Gill’s
haematoxylin.
Intraepithelial CD8
þ TILs located in direct contact with tumour
cells were quantified over the area of the entire punch for each case
in the TMA. Evaluation of other immunohistochemical markers
was performed semiquantitatively by assessing the proportion of
immunoreactive tumour cells over the total number of tumour
cells per TMA punch. A score ranging from 0 to 100% was ascribed
to each tumour based on 5% intervals.
Selection of rectal cancers and clinicopathological data
Tumours located in the colon (N¼938) were excluded from the
study. Analysis was restricted to carcinomas of the rectum and
included 482 cases. All rectal cancers were preoperatively
untreated. The clinicopathological features for these patients
included gender, pT and pN stage, tumour grade, vascular
invasion, mismatch-repair status and number of lymph nodes
collected after resection (Table 1). The mean of age at diagnosis
and of tumour diameter was 68.7 years (range: 36–96 years) and
46mm (5–125mm), respectively. Average number of lymph nodes
collected was 11.8 (range: 0–61). For 90 patients, cause of death or
status at the last follow-up was unknown and these patients were
excluded from survival analysis. Survival time was therefore
obtained for 392 patients. Follow-up ranged from 0 to 150 months
with a median of 51 months. The 5-year cancer-specific survival
time was 54% (95% confidence interval (CI): 49–59). Censored
observations were defined as patients who were alive, lost to
follow-up or suffered death from reasons other than rectal cancer
up until 5-years following surgery. For 118 patients, information
on the presence or absence of distant metastasis, local recurrence
and postoperative therapy was available.
Receiver operating curve (ROC) analysis
The cutoff scores for protein marker positivity were determined by
ROC curve analysis (Zlobec and Lugli, 2008). This method can be
used to determine the optimal cutoff points for protein marker
expression when scored semiquantitatively, as was done in this
study. At each expression score, the sensitivity and specificity for
survival is determined and plotted, thereby generating an ROC
curve. Using the (0, 1) criterion, the point on the curve that
minimises the trade-off between sensitivity and specificity, thus
having the shortest distance to the coordinate (0, 1), is chosen and
patients are classified accordingly as positive or negative around
this corresponding protein expression value. It should be noted
that although prognosis is generally considered a time-to-event
Table 1 Clinicopathological features of rectal cancer patients
Frequency
Clinicopathological feature No. available % Total (n)
Sex
Male 251 52.1 482
Female 231 47.9
pT stage
pT1 29 6.1 475
pT2 112 23.6
pT3 301 63.4
pT4 33 7.0
pN stage
pN0 238 52.2 456
pN1 122 26.8
pN2 96 21.1
Tumour grade
G1 and G2 443 93.5 474
G3 31 6.5
Vascular invasion
Absent 346 73.0 474
Presence 128 27.0
Invasive margin
Pushing 176 37.1 474
Infiltrating 298 62.9
Mismatch repair
Proficient 451 93.6 482
Deficient 31 6.4
Recurrence
Absent 62 53.9 115
Present 53 46.1
Metastasis
Absent 104 88.1 118
Present 14 11.9
Postoperative therapy
None 91 78.5 116
Radiotherapy 5 4.3
Chemotherapy 11 9.5
Radiochemotherapy 9 7.8
Survival
No. deaths 226 57.7% 392
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established and to date can not be implemented with ease for the
cutoff point determination over time (Heagerty et al, 2000). For
this reason, standard ROC curve analysis was used in this study
and is expected to yield the best cut off value for markers to
discriminate between patients who have died from disease vs those
alive or censored after 5 years.
Statistical analysis
Univariate survival analysis using Cox proportional hazards
regression was performed for each protein marker. The assump-
tion of proportional hazards was verified before each analysis.
Hazard ratios (HRs), 95% CI and P-values were used to determine
the effect of each protein marker on survival time. In the case of
protein markers, the baseline hazard of 1.0 was systematically
attributed to negative protein expression. HR 41.0 indicate
an adverse prognosis with positive expression, whereas HR o1.0
indicate improved prognosis with marker positivity. To determine
the reliability of the prognostic effects of markers significant in
univariate analysis, bootstrapped replications of the data were
analysed. This approach allows one to sample the data with
replacement, for example, 1000 times resulting in 1000 different
‘resamples’ of the original dataset. For each of these resamples,
multiple Cox regression analysis was performed using a forward
selection procedure. The number of times a particular marker was
selected as an independent factor, after adjustment for the
remaining variables, was determined. The most reliable indepen-
dent markers were combined into multimarker phenotypes with
different combinations of their negative or positive expressions.
Kaplan–Meier survivals curves were analysed using the log-rank
test. w
2-Tests were performed to determine the association of
marker expression on the absence or presence of local recurrence.
P-values were two-sided and considered statistically significant if
o0.05. Analyses were performed using SAS (9.1, The SAS Institute,
NC, USA).
RESULTS
Survival analysis
Univariate analysis The expression of four markers was asso-
ciated with survival time including negative expression of Ki67
(P¼0.033; HR¼0.72 (0.53–0.97)), positivity for RHAMM
(Po0.001; HR¼2.19 (1.65–2.91)), absence of RKIP (P¼0.015;
HR¼0.69 (0.51–0.93)) and loss of CD8
þ TILs (Po0.001;
HR¼0.55 (0.41–0.74); Table 2).
Reliability of prognostic markers
Ki67, RHAMM, RKIP and CD8
þ TILs were entered into multi-
variable analysis with a selection procedure. For each of the 1000
resamples, only those markers, which remained significantly
associated with survival time after adjustment for the prognostic
effects of the remaining markers during forward selection
(Po0.05) were selected. The most frequently selected markers
were considered the most reliable prognostic factors. Out of the
1000 resamples, RHAMM, CD8
þ TILs, Ki67 and RKIP were
selected 990, 854, 244 and 69 times, respectively as prognostic
factors.
Multivariable analysis
The receptor for hyaluronic acid-mediated motility and CD8
þ
TILs, determined to be the most valuable markers, were entered
into a second multivariable analysis along with clinicopathological
features that are available at the time before surgery, namely pT
stage, pN stage and age at diagnosis (Table 3). Positivity for
RHAMM (Po0.001; HR¼1.94 (1.44–2.61)) and loss of CD8
þ
TILs (P¼0.006; HR¼0.63 (0.45–0.88)) maintained their signifi-
cant adverse effect on survival time.
Two-marker protein profile
The receptor for hyaluronic acid-mediated motility and CD8
þ
TILs were combined into their four possible pheno-
types (RHAMMþ/TILþ, RHAMMþ/TIL , RHAMM /TILþ
and RHAMM /TIL ). The Kaplan–Meier survival curve in
Figure 1 highlights considerable differences between the four
phenotypes with RHAMMþ/TIL  tumours having significantly
worsened (Po0.001) survival time compared to RHAMM /TILþ
tumours. Moreover, the 5-year survival rate for patients with
RHAMMþ/TIL  tumours was 30% (95% CI: 21–40%) compared
to 76% (95% CI: 66–84%) for RHAMM /TILþ patients.
Figure 2A illustrates the survival time in patients with early T1,
T2 tumours with the adverse RHAMMþ/TIL  phenotype. The
5-year cancer-specific survival rate of these patients was 48% (95%
CI: 20–72%), whereas for patients with the more favourable
marker combination RHAMM /TILþ, a 5-year survival rate of
84.4% (95% CI: 68–93%) was observed. Compared to the
Table 2 Association of protein marker expression and 5-year cancer-specific survival time in patients with rectal cancer (univariate analysis; Cox
proportional hazards regression)
Protein marker Cutoff score Negative N (%) Positive N (%) HR (95% CI) P-value
APAF-1 90% 226 (53.2) 199 (46.8) 0.98 (0.74–1.29) 0.876
EphB2 70% 150 (39.8) 227 (60.2) 0.92 (0.66–1.27) 0.549
Ki67 15% 221 (57.6) 163 (42.5) 0.72 (0.53–0.97) 0.033
MST1 70% 124 (31.2) 274 (68.8) 0.76 (0.56–1.02) 0.068
p53 20% 199 (46.9) 225 (53.1) 1.08 (0.82–1.42) 0.584
RHAMM 90% 239 (59.3) 164 (40.7) 2.19 (1.65–2.91) o0.001
RKIP 80% 128 (34.5) 243 (65.5) 0.69 (0.51–0.93) 0.015
CD8
+ TILs four cells/HPF 275 (60.0) 183 (40.0) 0.55 (0.41–0.74) o0.001
HPF¼high-power field; HR¼hazard ratios; CI¼confidence interval.
Table 3 Association of RHAMM and CD8
+ TILs after adjusting for the
prognostic effect of pT stage, pN stage, age and tumour diameter
(multivariable analysis; Cox proportional hazards regression)
P-value HR (95% CI)
pT stage o0.001 2.52 (1.61–3.94)
pN stage o0.001 1.98 (1.44–2.71)
Age o0.001 1.03 (1.02–1.05)
RHAMM o0.001 1.94 (1.44–2.61)
CD8
+ TILs 0.006 0.63 (0.45–0.88)
HR¼hazard ratio; CI¼confidence interval.
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TILþ tumours had a significantly better prognosis (P¼0.039) and
5-year survival rate of 71% (95% CI: 56–82%). Only late T3, T4
patients with RHAMMþ/TIL  tumours performed significantly
worse than patients with early T-stage tumours of adverse
RHAMMþ/TIL  phenotype.
Similar observations were made in Figure 2B for patients with
node-negative (N0) RHAMMþ/TIL  tumours compared with
node-positive (Nþ) patients. Only Nþ tumours with the
RHAMMþ/TIL  phenotype demonstrated a significantly worse
prognosis (P¼0.005), with 5-year cancer-specific survival rate
of 15% (95% CI 6–28%), compared with N0 tumours with the
adverse RHAMMþ/TIL  phenotype (the 5-year survival rate:
53% (95% CI 35–69%)).
Local recurrence
The receptor for hyaluronic acid-mediated motility and CD8
þ
TILs were tested for their association with local recurrence. In
total, 87 patients with information on local recurrence were also
evaluable for both markers of which 44.9% (n¼39) had local
failure. Neither RHAMM (P¼0.606) nor CD8
þ TILs (P¼0.386)
were predictive of this end point on their own. A highly significant
statistical interaction (P¼0.006) was observed between the two
markers indicating that the effect of CD8
þ TILs on local
recurrence is modified by the negative or positive expression of
RHAMM. These results are shown in Table 4. Loss of CD8
þ TILs
is significantly linked to the presence of local recurrence in
RHAMM-positive tumours (P¼0.009), a result which is not
observed in RHAMM-negative patients.
DISCUSSION
Biological markers for identifying rectal cancer patients at high
risk of poorer clinical outcome would improve the selection of
patients for preoperative therapy. In this study on 482 rectal
cancers, we document that combined negativity for CD8
þ TILs
and over-expression of the marker RHAMM leads to adverse
survival independently of disease stage. Using a resampling
technique, we determined that the prognostic effect of these two
markers was remarkably reproducible in multivariable analysis.
The novel findings of this study show that the combined
immunohistochemical profile of RHAMMþ/TIL  accurately
predicts a highly adverse prognosis in patients with early stage
disease. In particular, patients with T1, T2 tumours with this
unfavourable protein profile have a 5-year cancer-specific survival
rate similar to patients with T3 or T4 cancers. Similarly, N0
patients with RHAMMþ/TIL  tumours were found to have
comparable survival times to patients with Nþ cancers. These
findings indicate that immunohistochemical analysis of CD8
þ
TILs and RHAMM expression can not only refine prognostic
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Figure 1 Kaplan–Meier survival curves and cancer-specific survival rates
for combinations of RHAMM and CD8
þ tumour infiltrating lymphocytes
(TILs) (Po0.001).
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Figure 2 (A) Comparison of Kaplan–Meier survival curves and cancer-
specific survival rates for early T1 and T2 patients with the highly adverse
RHAMMþ/TIL  phenotype compared with late T3 and T4 patients. (B)
Comparison of Kaplan–Meier survival curves cancer-specific survival rates
for node-negative (N0) patients with the highly adverse RHAMMþ/TIL 
phenotype compared with node-positive (Nþ) patients.
Table 4 Interaction between RHAMM expression and CD8
+ TIL and
their effect on local recurrence
CD8
+ TILs No. (%)
RHAMM expression Recurrence Negative Positive P-value
Negative
Absent 18 (58.1) 13 (41.9) 0.228
Present 17 (73.9) 6 (26.1)
Positive
Absent 12 (70.6) 5 (29.4) 0.009
Present 4 (25.0) 12 (75.0)
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ssubgroups in rectal cancer but could be utilised to identify a
subgroup of early rectal cancer patients at high risk of adverse
prognosis.
An understanding of the biological function of these two protein
markers further clarifies their contribution to prognosis. Although
few studies have specifically targeted the evaluation of CD8
þ TILs
in rectal cancer, several groups, including ours have previously
identified intraepithelial TIL positivity as a favourable prognostic
indicator in colorectal cancers, especially those characterised by
microsatellite stability, a feature shared by the majority of rectal
cancers (Baker et al, 2007). We have additionally reported the
impact of absence of CD8
þ TILs on local recurrence rates in
mismatch repair-proficient colon cancer (Zlobec et al, 2008c). The
close proximity of activated cytotoxic T cells to the tumour cells
may allow for initiation of an effective antitumour immune
response despite the generally immunosuppressive nature of the
gut (Montufar-Solis et al, 2007). Furthermore, the presence of
intraepithelial TILs likely reflects an active peripheral immune
response capable of efficiently eradicating micrometastases and
thereby contributing to prolonged patient survival. In this study,
we find that the loss of CD8
þ TILs is also linked to local
recurrence in rectal tumours, but only in the context of RHAMM
positivity.
The receptor for hyaluronic acid-mediated motility is a multi-
functional glycoprotein often upregulated in advanced malignan-
cies and has been identified as an adverse prognostic marker in
both colorectal and breast cancers (Hamilton et al, 2007; Zlobec
et al, 2008b). We have recently identified RHAMM in combination
with p21 as highly conducive towards a severely adverse prognosis
in microsatellite instability-high (MSI-H) colorectal cancer (Zlobec
et al, 2008a). When expressed at the cell surface, RHAMM serves as
a receptor for hyaluronic acid and has been implicated in both
tumour cell motility and invasiveness (Hardwick et al, 1992)
. In N0
rectal cancers, RHAMM positivity may be indicative of a
particularly invasive tumour phenotype prone to the release of
micrometastases from the primary tumour. The dismal prognosis
of patients with rectal cancers simultaneously negative for
intraepithelial CD8
þ TILs and overexpressing RHAMM may thus
arise because of the failure of the host’s immune system to contain
an exceptionally motile type of cancer.
On the one hand, our study is limited by the fact that
preoperative biopsies were not themselves analysed. Rather tissue
punches from the central part of the tumour were used for
immunohistochemistry. Our results, therefore, will require valida-
tion in a prospective setting. Additionally, survival time in patients
with rectal cancer is known to be linked to surgical procedure. As
our rectal cancer specimens were collected from 1987 to 1996,
many of the patients included here predate the TME as the gold
standard in care for advanced stage rectal cancer. This may explain
to some degree the relatively higher frequency of local failure in
our series. Interestingly, we found the rate of distant metastasis to
be only 12%. We hypothesise that this may be related to the
frequency of mismatch repair-deficient tumours in this study,
which may be greater than the expected. Although little is known
about the incidence of microsatellite instability specifically in
rectal cancer, lower rates of distant metastasis have been observed
in patients with this feature in colorectal cancer in general. In
addition, because of the small number of people in our study
treated in the adjuvant setting, we could not reliably test whether
the prognostic effect of the marker combination RHAMM and
CD8
þ TILs is maintained after postoperative therapy. The poor
prognosis in the subgroup of patients with RHAMMþ/TIL 
tumours is independent of pT or pN stage suggesting that this
multimarker phenotype could be helpful in selecting patients for
adjuvant chemotherapy.
Our study is strengthened by the TMA technique, which has
allowed us to study eight different markers on 482 tumours. In
conjunction with the described scoring method and ROC curve
analysis, the use of TMAs has been shown to promote strong
interobserver agreement between independent pathologists (Zlo-
bec and Lugli, 2008). Moreover, all patients were preoperatively
untreated in this series, and so no adjustments for the possible
effects of neoadjuvant therapy were required.
This study strongly suggests that the two-marker immunohis-
tochemical protein profile of RHAMM and CD8
þ TILs can identify
patients with adverse prognosis independent of the extent of
disease. Added to the preoperatively available array of patient
information, the combined analysis of RHAMM and CD8
þ TILs
could assist in selecting early stage rectal cancer patients most
likely to be facing a particularly poor prognosis and who may
derive the most benefit from preoperative therapy.
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